SAMHD1 as a prognostic and predictive biomarker in stage II colorectal cancer: A multicenter cohort study

BACKGROUND: The identification of high-risk population patients is key to the personalized treatment options for the stage II colorectal cancers. The use of proteomics in the prognosis of patients with stage II colorectal cancer remains unclear. METHODS: Using quantitative proteomics, we analyzed pr...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Dingyun, Zhang, Shuai, Yan, Shan, Ding, Yingying, Li, Chunxia, Cheng, Xianshuo, Wu, Lin, Wang, Weizhou, Zhang, Tao, Li, Zhenhui, He, Yongwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376296/
https://www.ncbi.nlm.nih.gov/pubmed/35978833
http://dx.doi.org/10.3389/fonc.2022.939982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376296/
https://www.ncbi.nlm.nih.gov/pubmed/35978833
http://dx.doi.org/10.3389/fonc.2022.939982

Ejemplares similares